Clinically driven target lesion revascularization (TLR) appears to be associated with an increased risk of cardiac death or myocardial infarction (MI) in patients who receive either a bare-metal stent (BMS) or a sirolimus-eluting stent (SES), according to a new analysis of data from the SIRIUS trial published online August 2, 2010, ahead of print in the American Journal of Cardiology. The double-blinded SIRIUS (Sirolimus-Eluting Stent in De Novo Native Coronary Lesions) trial randomized 1,058 patients with de novo coronary artery lesions to either SES (Cypher, Cordis/Johnson & Johnson, Miami Lakes, FL; n = 533) or BMS (n = 525).
